CAI (Caris Life Sciences) Ending Cash Position: $692.7 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI Caris Life Sciences Inc CAI
12 GF Score
Price $22.39
! 4 Warning Signs
View Full Analysis

What is Caris Life Sciences Ending Cash Position?

Caris Life Sciences CAI -3.22% 12 Ending Cash Position is $692.7 Mil as of Jun. 2026. GuruFocus rates CAI with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Caris Life Sciences's Ending Cash Position for the quarter that ended in Jun. 2026 was $692.7 Mil.

Caris Life Sciences's quarterly Ending Cash Position increased from Dec. 2025 ($800.0 Mil) to Mar. 2026 ($823.4 Mil) but then declined from Mar. 2026 ($823.4 Mil) to Jun. 2026 ($692.7 Mil).

Caris Life Sciences's annual Ending Cash Position increased from Dec. 2023 ($60.0 Mil) to Dec. 2024 ($68.0 Mil) and increased from Dec. 2024 ($68.0 Mil) to Dec. 2025 ($800.0 Mil).

Caris Life Sciences Ending Cash Position Related Terms

Caris Life Sciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Caris Life Sciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caris Life Sciences Ending Cash Position Chart

Caris Life Sciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
111.14 60.01 68.03 800.04

Caris Life Sciences Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 722.69 756.98 800.04 823.39 692.75
CAI
12GF Score
Caris Life Sciences Inc CAI
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caris Life Sciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Caris Life Sciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=68.028+732.014
=800.0

Caris Life Sciences's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=823.39+-130.645
=692.7

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $692.7 Mil mean?
Caris Life Sciences (CAI) has a Ending Cash Position of $692.7 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Caris Life Sciences and its competitors.
Is Caris Life Sciences' Ending Cash Position too high?
Caris Life Sciences' current Ending Cash Position is $692.7 Mil. Overall, Caris Life Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' Ending Cash Position compare to EWTX and TNGX?
Caris Life Sciences' Ending Cash Position of $692.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Caris Life Sciences and its competitors. Caris Life Sciences's current Ending Cash Position is $692.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current Ending Cash Position of $692.7 Mil. The current Ending Cash Position is $692.7 Mil. Caris Life Sciences' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current Ending Cash Position is $692.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Caris Life Sciences Business Description

Other Exchanges CAI:Mexico49J:Germany
Address 750 W. John Carpenter Freeway, Suite 800, Irving, TX, USA, 75039
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
12GF Score

Get the complete analysis for CAI

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.39
Price